Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus DEMECLOCYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus DEMECLOCYCLINE HYDROCHLORIDE.
DECLOMYCIN vs DEMECLOCYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic